Gameto Unveils New Data on In Vitro Maturation Product Candidate Fertilo During Four Presentations at the 2023 American Society for Reproductive Medicine
Retrieved on:
Thursday, October 19, 2023
Gold, Human, Cell engineering, Fertility, RMA, IVM, RNA, Biotechnology, Spindle apparatus, Congress, Research, Society, F1, Reproductive medicine, IVF, Egg, Oocyte, Cell, Partnership, Behavior informatics, Abstract, American Society for Reproductive Medicine, ASRM, Woman, Safety, Patient, Gene expression, Mineral oil
Gameto's findings show their product candidate, Fertilo, is able to improve egg maturation and embryo development in shortened human minimal stimulation cycles.
Key Points:
- Gameto's findings show their product candidate, Fertilo, is able to improve egg maturation and embryo development in shortened human minimal stimulation cycles.
- The combined findings are an important evidence package as a next step in advancing this reproductive technology.
- NEW YORK, Oct. 19, 2023 /PRNewswire/ -- Gameto, a female-led biotechnology company with a mission to redefine women's healthcare, presented four abstracts at the 2023 American Society for Reproductive Medicine (ASRM) Congress.
- The findings show that Fertilo not only matures more eggs, but results in better gene expression and genetic health quality than traditional IVM.